RPRX

Royalty Pharma Plc

A buyer of biopharmaceutical royalties: it pays universities, hospitals, foundations, and drugmakers upfront cash in exchange for a share of future sales of approved and late-stage medicines like Vertex's Trikafta cystic fibrosis treatment and Xtandi. Founded in 1996 by former Lazard banker Pablo Legorreta, who got the idea after watching a chemotherapy royalty investment pay off, it grew into one of the world's largest acquirers of drug royalty streams. Notably, it never develops drugs itself—it simply collects a slice of the top-line sales of treatments others make and sell.

CINS: G7709Q104CUSIP: G7709Q104HealthcareUS5 holders

Ownership Activity Financials Filings

RPRX

RPRX

Results of Operations and Financial Condition

Submission of Matters to a Vote of Security Holders

Entry into a Material Definitive Agreement

Results of Operations and Financial Condition

Regulation FD Disclosure

Results of Operations and Financial Condition

Regulation FD Disclosure

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements